Meet Agendia at 2026 SABCS®

Explore how MammaPrint® and BluePrint® bring recurrence-risk and molecular-subtype insights into treatment planning for early-stage breast cancer.

Meeting: – San Antonio, Texas Booth #1242 Exhibits: –

WHY MEET AGENDIA AT SAN ANTIONIO 2026?

Genomic insights for better decisions
in early-stage breast cancer

Mammaprint info card

MammaPrint

Learn the likelihood of a patient’s breast cancer recurring.

BluePrint info card

BluePrint

Determine the underlying genomics driving the growth of a tumor.

Ongoing trials events

Ongoing Trials

See clinical trials advancing genomic-guided care in early breast cancer.

NEW DATA TO BE PRESENTED

New MammaPrint + BluePrint Data at San Antonio 2026

Explore research on genomic risk and molecular subtyping in early-stage breast cancer.

Rapid Fire Presentation

Excellent Long Term Outcomes Irrespective of Chemotherapy Use or Age for Clinically High and Genomically UltraLow Risk Early Breast Cancer in the MINDACT trial

  • Presenting Author Prof. Laura van ‘t Veer
  • Presentation # RF8-1
  • Location Stars at Night 1–2
  • Session Date/Time
    – CST
Poster

Molecular subtyping, pathologic complete response, and immune profiling of germline BRCA1/2-mutated HR+/HER2− breast cancer in the FLEX study

  • Presenting Author Amir Sonnenblick
  • Presentation # P3-4-18
  • Location Exhibit Hall
  • Date/Time
    – CST
Poster

Genomic Characterization of ER-Low Breast Cancer in the Real-World FLEX Registry: Distinct Biology and Outcomes Defined by 70-Gene Recurrence Risk and 80-Gene Molecular Subtyping assays

  • Presenting Author Danilo Giffoni
  • Presentation # P3-10-01
  • Location Exhibit Hall
  • Date/Time
    – CST
Poster

80-gene molecular subtyping assay informs neoadjuvant platinum-based treatment selection and predicts high pathologic complete response in HR+/HER2− breast cancer

  • Presenting Author Joyce O'Shaughnessy
  • Presentation # P3-10-20
  • Location Exhibit Hall
  • Date/Time
    – CST
Poster

Association of CD47 expression with the 70-gene genomic risk assay, 80-gene molecular subtyping, and clinical outcomes in early breast cancer

  • Presenting Author Rakhshanda Layeequr Rahman
  • Presentation # P5-7-19
  • Location Exhibit Hall
  • Date/Time
    – CST

PROGRAM

Research to Practice

Register to attend this Research To Practice CME dinner program in person in San Antonio or virtually via live webcast.

Research to practice program 2026

ABOUT

Breast Cancer Research in San Antonio

From December 8–11, 2026, clinicians, researchers, and patient advocates from around the world will gather in San Antonio to exchange perspectives on breast cancer research and care.

Connect with Agendia to discuss the role of genomic testing in early-stage breast cancer. Meet with our team to learn more about MammaPrint®, BluePrint®, and our ongoing research.

This page is independently managed by Agendia and provides information about our participation in 2026 SABCS®. It is not sponsored or endorsed by the symposium organizers.

Meet with Agendia at the 2026 San Antonio events

THE MAMMAPRINT + BLUEPRINT TEST SUITE
Analyze over a hundred relevant genes at once.

With the additional results of BluePrint, our molecular subtyping test, physicians gain an even broader genomic profile. From just one tumor block, you can interrogate over 150 genes containing information on a tumor’s level of aggression and potential for growth. These insights will serve as an essential resource for guiding your pre- and post-operative treatment strategies.

MammaPrint BluePrint test suite
Breast cancer healthcare provider

Agendia’s Healthcare Provider Newsletter

Subscribe to receive periodic updates on the latest MammaPrint + BluePrint data and upcoming meeting announcements, including ESMO.

Agendia MammaPrint + BluePrint

MammaPrint + BluePrint answer multiple clinical questions in just 6 days from core biopsy to optimize treatment in patients with HR+/HER2- early-stage breast cancer.